Clinical Trial Search

Primary: Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score — -5.4; -7.1; -2.9; -6.8 score on a scale — p=0.0813

Primary: Change From Baseline at Week 8 in the Numeric Pain Rating Scale (NPRS) Score — -3.29; -3.25; -2.75 score on a scale

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date — 2; 2 Participants

Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 4; 2; 1; 2 Participants

Primary: Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) — -5.94; -4.27 score on a scale — p=0.1983

Primary: Visual Acuity With Study Lenses at Week 1 Follow-Up — -0.12; -0.11 logMAR

Primary: Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)…

Primary: Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population — -1.86; -4.29 migraine days per month — p=<0.0001

Primary: A1C — 8.7; 8.6 percentage of glycosylated hemoglobin

Primary: Percentage of Participants Retained and Virally Suppressed Among Those Receiving the DTP Versus ICM Arms — 16.0; 14.1 percentage of participants — p=0.455

Primary: Fibroblast Growth Factor (FGF) 23 Mean Change From Baseline — -62.96; 9.08 RU/mL — p=0.037

Primary: Maximum Tolerated Dose of Ponatinib, Phase I — 30 mg of ponatinib

Primary: Change From Baseline at Week 6 on the Modified Ashworth Scale (MAS) in the Suprahypertonic Muscle Group (SMG) Score — -0.9; -1.0; -1.5; -0.8 score on a scale — p=0.7645

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 — -1.53; -1.25 Percentage of HbA1c — p=<.001